List of Excipients in Branded Drug BASIC CARE IBUPROFEN

Generic Drugs Containing BASIC CARE IBUPROFEN

Company	Ingredient	NDC	Excipient
L Perrigo Company	ibuprofen	0113-0788	ACESULFAME POTASSIUM
L Perrigo Company	ibuprofen	0113-0788	AMMONIUM GLYCYRRHIZATE
L Perrigo Company	ibuprofen	0113-0788	ASPARTAME
L Perrigo Company	ibuprofen	0113-0788	CARNAUBA WAX
L Perrigo Company	ibuprofen	0113-0788	CROSCARMELLOSE SODIUM

What are the Most Frequently-Used Excipients in BASIC CARE IBUPROFEN?

# Of NDCs	Excipient
1	ACESULFAME POTASSIUM
3	AMMONIA
1	AMMONIUM GLYCYRRHIZATE
1	ASPARTAME
1	CARNAUBA WAX

BASIC CARE Ibuprofen Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

BASIC CARE Ibuprofen is an over-the-counter, 200 mg ibuprofen product positioned as a value-oriented private-label analgesic and antipyretic. Its commercial opportunity does not depend on active-ingredient exclusivity. It depends on manufacturing cost, tablet performance, packaging, retail placement, dosage-form differentiation, and compliance with the FDA’s OTC ibuprofen monograph.

The product has no meaningful drug-patent barrier. Ibuprofen is a mature generic active ingredient with extensive supplier capacity and established regulatory pathways. Excipient selection can still affect margin, consumer acceptance, manufacturing yield, stability, swallowing performance, and the ability to launch differentiated versions such as softgels, liquid gels, pediatric suspensions, and combination products.

What is BASIC CARE Ibuprofen?

BASIC CARE Ibuprofen is a store-brand or value-brand OTC medicine containing ibuprofen, generally at a 200 mg single-unit dose. Basic Care products are sold through retail and e-commerce channels, including Amazon-linked distribution and other private-label outlets. Product configurations can differ by package size, dosage form, manufacturer, and market channel.

Product profile

Attribute	Assessment
Brand	BASIC CARE
Active ingredient	Ibuprofen
Typical strength	200 mg
Drug class	Nonsteroidal anti-inflammatory drug, or NSAID
Primary indications	Temporary relief of minor aches and pains and reduction of fever
U.S. regulatory pathway	OTC monograph pathway
Prescription requirement	None for compliant OTC products
Biosimilar exposure	None
Generic substitution	Commercially relevant, but the product is itself a private-label generic
Patent dependence	Minimal
Main value drivers	Cost, availability, dosage form, packaging, retailer placement, and quality

FDA labeling for OTC ibuprofen generally permits use for temporary relief of minor aches and pains due to the common cold, headache, toothache, muscular aches, backache, minor arthritis pain, menstrual cramps, and temporary reduction of fever, subject to the applicable labeling requirements.[1]

What excipients are used in BASIC CARE Ibuprofen?

The precise excipient profile depends on the specific BASIC CARE Ibuprofen SKU. Conventional 200 mg ibuprofen tablets and caplets commonly use a combination of fillers, binders, disintegrants, lubricants, glidants, coating agents, and colorants.

Likely excipient functions

Excipient class	Common examples	Commercial function
Diluent	Microcrystalline cellulose, starch, lactose, dibasic calcium phosphate	Adds bulk and controls tablet weight
Binder	Povidone, pregelatinized starch, hypromellose	Improves granule and tablet integrity
Disintegrant	Croscarmellose sodium, sodium starch glycolate, crospovidone	Promotes tablet breakup after ingestion
Lubricant	Magnesium stearate, stearic acid	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Surfactant or wetting agent	Sodium lauryl sulfate or similar material	Improves wetting of poorly water-soluble ibuprofen
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, mineral-based colorants	Improves appearance, handling, taste, and swallowability
Capsule shell	Gelatin or hypromellose	Used for softgel or hard-capsule formats
Suspension system	Cellulosic polymers, xanthan gum, polysorbate, glycerin, sorbitol	Supports pediatric liquid dosage forms

Ibuprofen is practically insoluble in water. That property creates a formulation challenge. Excipients must support rapid wetting, dispersion, disintegration, and dissolution without creating excessive tablet hardness or manufacturing defects.

A conventional immediate-release tablet does not require a novel excipient. The commercial objective is usually to meet dissolution and content-uniformity requirements at the lowest total cost while maintaining acceptable appearance and package stability.

How should the excipient strategy be optimized?

The strongest strategy is a cost-controlled immediate-release platform with targeted improvements in disintegration, manufacturability, and consumer handling.

1. Improve wetting and dissolution

Ibuprofen’s low aqueous solubility can limit dissolution performance. A formulation team can evaluate:

• Surfactant-assisted wetting
• Smaller active-particle size
• Micronized ibuprofen
• Granulation with controlled liquid addition
• Superdisintegrants
• Better powder deagglomeration
• Solubilizing or dispersing excipients compatible with the OTC dosage form

The commercial benefit is faster onset positioning, improved batch robustness, and lower dissolution variability. Any onset claim would require supporting evidence and compliant labeling.

2. Reduce tablet weight and improve swallowability

A smaller or smoother caplet can improve consumer acceptance. This can be achieved through:

• Higher-density diluents
• Direct compression excipient systems
• Lower coating weight
• Optimized tablet geometry
• Film coating with improved slip and moisture resistance
• Reduced inactive-mass burden

A smaller tablet is commercially useful in family packages and for consumers who find standard caplets difficult to swallow.

3. Increase manufacturing yield

Ibuprofen formulations can create sticking, picking, capping, and weight-variation problems. Excipient optimization should focus on:

• Lubricant concentration and blending time
• Granule size distribution
• Compression-force control
• Flow improvement
• Tooling geometry
• Moisture control
• Reduced over-lubrication

The most valuable formulation change is often one that reduces rejects, press downtime, and cleaning frequency rather than one that creates a new consumer claim.

4. Control moisture and packaging interaction

Moisture can affect tablet hardness, disintegration, coating integrity, and long-term stability. Packaging options include:

• High-barrier HDPE bottles
• Induction seals
• Desiccant canisters
• Unit-dose blister packs
• Child-resistant closures
• Moisture-resistant film coatings

Blister packaging can support travel and dose tracking, while bottles generally offer lower packaging cost for high-volume value channels.

What formulations are commercially protected or differentiable?

BASIC CARE Ibuprofen’s strongest commercial opportunities are dosage-form and user-experience extensions rather than patent-protected versions of the conventional tablet.

Immediate-release tablets and caplets

This is the lowest-cost platform and the most direct competitor to store-brand ibuprofen products. Differentiation can come from:

• Smaller tablets
• Rapid disintegration
• Easy-open packaging
• 100-count, 200-count, and 500-count formats
• Twin packs
• Club-store configurations
• Transparent value pricing

Patent protection is unlikely to be commercially meaningful for a standard 200 mg immediate-release tablet unless a company develops a genuinely novel manufacturing or delivery system.

Softgels and liquid gels

Softgels can improve swallowability and consumer perception. They may also support faster dispersion because ibuprofen is pre-dissolved or suspended in a liquid fill. The tradeoffs are:

• Higher unit cost
• Greater capsule-shell and fill-material sensitivity
• More complex encapsulation
• Higher packaging and stability requirements
• Potential licensing or contract-manufacturing dependence

A softgel platform can command a higher retail price than a basic tablet while retaining the same active ingredient.

Pediatric oral suspension

Pediatric ibuprofen creates an opportunity for excipient-led differentiation. Key formulation requirements include:

• Accurate dose delivery
• Palatable flavor
• Uniform suspension
• Resuspendability after storage
• Appropriate viscosity
• Preservative control
• Child-resistant packaging
• Dosing syringe compatibility

The excipient system can become commercially important because taste, pourability, sedimentation, and syringe accuracy directly affect repeat purchase.

Combination products

Potential combinations include ibuprofen with acetaminophen, decongestants, antihistamines, or other OTC actives. These products create higher regulatory and formulation complexity. Excipient selection must address:

• Chemical compatibility
• Dose uniformity
• Different dissolution requirements
• Labeling complexity
• Increased adverse-effect warnings
• Larger tablet size or multiple dosage forms

Combination products can expand basket size but raise regulatory and safety-management costs.

What is the FDA regulatory status of BASIC CARE Ibuprofen?

OTC ibuprofen products are generally regulated under the FDA’s OTC monograph framework, including the ibuprofen provisions in 21 C.F.R. Part 343 and the FDA’s OTC monograph order system.[2][3]

A compliant product must satisfy requirements covering:

• Active ingredient and permitted strength
• Indications
• Directions
• Warnings
• Label format
• Dosage form
• Manufacturing controls
• Finished-product quality
• Adverse-event and postmarket obligations

A conventional OTC monograph product does not require a new drug application solely because it uses a different conventional excipient system. The excipients must be suitable for the dosage form and must not undermine safety, quality, performance, or required labeling.

Excipient regulatory considerations

A formulation change should be evaluated for:

• FDA inactive-ingredient acceptability
• Maximum historical use levels
• Route-specific exposure
• Allergy and intolerance considerations
• Nitrosamine and elemental-impurity risk where relevant
• Microbiological quality
• Supplier qualification
• Change-control documentation
• Dissolution and stability impact

Novel excipients can create a disproportionate regulatory burden for a low-price OTC product. Conventional, pharmacopeial-grade materials are usually commercially preferable.

What is the Orange Book status of BASIC CARE Ibuprofen?

BASIC CARE Ibuprofen is not principally protected through an Orange Book-listed patent estate. The Orange Book is most relevant to approved prescription and certain other NDA products, while a conventional OTC monograph ibuprofen product is generally governed by the monograph framework rather than by Orange Book exclusivity.[4]

Patent and exclusivity assessment

Issue	BASIC CARE Ibuprofen assessment
Active-ingredient patent	Expired
Standard tablet patent barrier	None of practical significance
Orange Book patent litigation	Generally not applicable to the monograph product
Paragraph IV challenge risk	Not a meaningful issue for a standard monograph product
Regulatory exclusivity	No product-specific exclusivity expected for a conventional monograph product
Biosimilar competition	Not applicable
Generic entry	Already established and extensive
Main IP opportunity	Formulation, manufacturing, packaging, or delivery-system claims

When does BASIC CARE Ibuprofen lose exclusivity?

BASIC CARE Ibuprofen has no meaningful product-specific exclusivity period to lose. Ibuprofen has long been available as a generic OTC active ingredient, and competing manufacturers can market compliant products through established pathways.

Commercial protection is instead created through:

• Retailer agreements
• Private-label supply contracts
• Capacity reservations
• Cost advantages
• Packaging formats
• Brand search visibility
• Quality performance
• Formulation know-how
• Manufacturing scale

This distinction matters for valuation. A conventional BASIC CARE Ibuprofen product should be assessed as a supply-chain and retail execution asset, not as a patent-protected pharmaceutical asset.

How strong is the patent estate for BASIC CARE Ibuprofen?

The patent estate is weak for the conventional product and potentially meaningful only for differentiated delivery or manufacturing technology.

Potentially protectable areas

A manufacturer could pursue patent protection for:

• Novel ibuprofen salt or co-crystal forms
• Rapid-release compositions
• Taste-masked pediatric suspensions
• Stabilized liquid formulations
• Softgel fill systems
• Abuse-deterrent or modified-release systems
• Continuous manufacturing processes
• Low-dust manufacturing methods
• High-load tablet compositions
• Moisture-resistant coating systems
• Unit-dose packaging with integrated dosing features

Patent value depends on whether the claims cover a commercially necessary feature and whether competing manufacturers can design around them. A broad patent on a standard excipient combination would face validity and obviousness pressure because ibuprofen formulation technology is mature.

Which companies are challenging BASIC CARE Ibuprofen?

No conventional Paragraph IV challenger dynamic is expected for a standard OTC monograph product. Competition comes from established OTC and private-label manufacturers, including:

• Perrigo
• Dr. Reddy’s Laboratories
• Haleon
• Kenvue
• CVS Health private label
• Walmart private label
• Walgreens private label
• Target private label
• Amazon-linked private-label suppliers
• Regional contract manufacturers

The relevant competitive question is not whether a generic will enter after patent expiry. It is whether another supplier can offer a lower landed cost, better service levels, stronger retailer economics, or a more attractive dosage form.

What commercial opportunities exist for BASIC CARE Ibuprofen?

Value-channel expansion

The largest near-term opportunity is high-volume, low-cost supply in:

• E-commerce multipacks
• Club-store bottles
• Travel-size packs
• Institutional procurement
• Employer and school first-aid programs
• Retail pharmacy private labels
• International private-label channels

Manufacturing scale and packaging procurement can have a greater effect on profitability than small changes in excipient cost.

Premium private-label extensions

A retailer can use the BASIC CARE platform to introduce:

• Coated mini-caplets
• Liquid gels
• Dye-free tablets
• Gluten-free positioning where substantiated
• Sugar-free pediatric suspension
• Single-dose blister packs
• Easy-open senior packaging
• Family pain-relief bundles
• Ibuprofen and acetaminophen combination products

These versions can raise average selling price, but the cost of clinical, regulatory, stability, and packaging work must be controlled.

Sustainable excipient and packaging positioning

Potential opportunities include:

• Lower-material blister formats
• Recyclable bottles
• Reduced coating load
• Supplier programs using lower-carbon manufacturing
• Paper-based secondary packaging
• Concentrated pediatric products that reduce shipping volume

Environmental claims require substantiation and careful labeling. The strongest economic case is usually packaging reduction and logistics efficiency.

What manufacturing and IP barriers affect the product?

The active ingredient is broadly available, so the principal barriers are operational:

• FDA-compliant manufacturing
• Reliable ibuprofen API sourcing
• Dissolution and content-uniformity control
• Tablet-press capacity
• Coating capacity
• Softgel or suspension manufacturing capability
• Packaging-line throughput
• Child-resistant packaging validation
• Stability data
• Retailer quality audits
• Recall and traceability systems

A supplier with an optimized high-speed compression process, low reject rate, and dependable packaging capacity can outperform a nominally cheaper supplier.

How does BASIC CARE Ibuprofen compare with branded Advil?

Factor	BASIC CARE Ibuprofen	Advil
Active ingredient	Ibuprofen	Ibuprofen
Typical consumer position	Value/private label	Branded
Patent advantage	Minimal	Minimal for conventional OTC forms
Price	Usually lower	Usually higher
Retail leverage	Retailer-controlled	Brand-driven
Formulation differentiation	Limited in basic tablet	Broader branded dosage-form portfolio
Marketing cost	Lower brand investment	Higher consumer-marketing investment
Margin strategy	Volume and procurement	Brand premium and product segmentation
Generic substitution risk	Inherent	High from private labels

BASIC CARE can compete effectively on price and availability. Advil retains advantages in brand recognition, advertising, product familiarity, and premium dosage-form extensions.

What generic launch risks exist for BASIC CARE Ibuprofen?

Generic launch risk is structurally high because the market is already commoditized. The main risks are:

1. Retail price compression.
2. Retailer replacement of one supplier with another.
3. API cost volatility.
4. Manufacturing-site disruption.
5. Product-quality failures or recalls.
6. Packaging shortages.
7. Consumer migration to softgels or combination products.
8. Retailer preference for exclusive private-label contracts.
9. FDA inspection or compliance problems.
10. Supply interruptions that reduce shelf availability.

A new entrant needs a cost or service advantage. A standard tablet with no packaging, distribution, or formulation differentiation is unlikely to support durable pricing power.

Key Takeaways

• BASIC CARE Ibuprofen is a mature OTC private-label product with no meaningful conventional patent moat.
• The relevant regulatory framework is the FDA OTC monograph pathway, not a typical Orange Book exclusivity strategy.
• Excipients should be selected to improve wetting, dissolution, compression, disintegration, stability, and swallowability at low cost.
• The strongest commercial opportunities are softgels, pediatric suspension, mini-caplets, combination products, travel packs, and retailer-specific packaging.
• Patent value is concentrated in novel delivery systems, manufacturing methods, liquid formulations, and packaging rather than standard tablet excipients.
• Revenue exposure is driven by retail contracts, supply reliability, manufacturing scale, and channel placement. Brand-specific revenue is not publicly reported as a separate line item.
• A conventional tablet faces immediate competition from multiple private-label and branded suppliers.
• The most credible investment thesis is operational efficiency and dosage-form expansion, not regulatory exclusivity.

FAQs

Can a new excipient create market exclusivity for BASIC CARE Ibuprofen?

Usually no. A new excipient may improve performance, but exclusivity requires enforceable intellectual-property claims and a product feature that competitors cannot readily design around.

Is micronized ibuprofen commercially useful in an OTC tablet?

Yes. Micronization can improve surface area, wetting, and dissolution, but it can also increase dusting, electrostatic behavior, and processing complexity. The benefit must justify added manufacturing controls.

Does BASIC CARE Ibuprofen need an ANDA?

A conventional U.S. OTC monograph product generally follows the monograph pathway rather than requiring an ANDA. A formulation outside the monograph or a product making unsupported claims may require a different FDA pathway.

Are ibuprofen softgels more defensible than ibuprofen tablets?

They can be more commercially differentiated, but softgels remain exposed to competing formulations, contract manufacturers, and design-around strategies. Their advantage is usually consumer positioning and margin, not automatic patent strength.

Which excipient is most important for ibuprofen dissolution?

No single excipient determines performance. Wetting agents, particle size, granulation, superdisintegrants, compression force, and lubricant levels work together to control dissolution.

References

1. U.S. Food and Drug Administration. (2024). Ibuprofen drug facts label and OTC analgesic requirements. FDA.

2. U.S. Food and Drug Administration. (2020). Over-the-counter monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products. FDA.

3. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. Office of the Federal Register.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.